What is L-Carnosine?
L-Carnosine is a dipeptide investigated in metabolic and cellular research. A small oral-supplement pilot examined insulin and glucose-related measures in adults without diabetes.
Biological role or research focus
Metabolic-marker supplementation research.
Small pilot and subgroup findings do not establish prevention of type 2 diabetes or treatment of neurological disease.
Role reference: Effects of carnosine supplementation on glucose metabolism: Pilot clinical trial. · 2016 ↗
Names you may encounter
Carnosine · Beta-alanyl-L-histidine
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Beta-alanyl-L-histidine dipeptide
- Research focus
- Metabolic-marker supplementation research
- Featured evidence
- Human randomized pilot trial
- Source check
- October 4, 2026
Source: Effects of carnosine supplementation on glucose metabolism: Pilot clinical trial. · 2016 ↗
Quick answers
- Is L-Carnosine FDA approved?
- No. No FDA-approved drug contains L-Carnosine. FDA lists it in 503A category 3: nominated for compounding without enough supporting information. Source ↗
- Is L-Carnosine safe?
- L-carnosine is a natural dipeptide sold as a supplement. Small oral studies found it generally tolerated, though very high intakes caused headache, nausea and tingling in one study. Human safety data: trials only. The Risks & interactions section below lists what is known. Read the risks ↓
- Is L-Carnosine banned in sport?
- It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Carnosine in overweight and obese adults (2016) | Human randomized pilot trial | 30 overweight or obese adults without diabetes. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized pilot trial · 2016
Carnosine in overweight and obese adults
What did this publication test, and what did it find?
- Population / model
- 30 overweight or obese adults without diabetes.
- Study design
- Twelve-week randomized placebo-controlled pilot with 15 participants per group.
- Main finding
- The supplemented group showed attenuation of increases in fasting insulin and insulin resistance. A subgroup analysis reported glucose-tolerance changes.
- Limits & context
- Small pilot and subgroup findings do not establish prevention of type 2 diabetes or treatment of neurological disease.
Source: Effects of carnosine supplementation on glucose metabolism: Pilot clinical trial. · 2016 ↗
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
33 registered studies name L-Carnosine as an intervention; 1 is recruiting or under way, 0 have not started recruiting yet, 21 completed and 11 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 33 listed studies.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
The role of Zinc L-Carnosine in the prevention and treatment of gastrointestinal mucosal disease in humans: a review. ↗
Clinics and research in hepatology and gastroenterology · 2022 Aug-Sep · Journal Article, Review
Carnosine and Beta-Alanine Supplementation in Human Medicine: Narrative Review and Critical Assessment. ↗
Nutrients · 2023 Apr 5 · Journal Article, Review
Read available full text ↗
Multi-omics signatures reveal genomic and functional heterogeneity of Cutibacterium acnes in normal and diseased skin. ↗
Cell host & microbe · 2024 Jul 10 · Journal Article, Research Support, Non-U.S. Gov't
Skeletal muscle hypertrophy rewires glucose metabolism: An experimental investigation and systematic review. ↗
Journal of cachexia, sarcopenia and muscle · 2024 Jun · Journal Article, Systematic Review, Research Support, Non-U.S. Gov't
Read available full text ↗
Risks & interactions
L-carnosine is a natural dipeptide sold as a supplement. Small oral studies found it generally tolerated, though very high intakes caused headache, nausea and tingling in one study.
Evidence comes from small, short oral trials, including a tolerability study in 16 volunteers and a 12-week pilot in 30 adults. Long-term safety and use alongside other conditions or medicines are not well studied.
It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Side effects reported in studies
- headache (at very high intakes)
- nausea (at very high intakes)
- tingling (at very high intakes)
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: Carnosine safety and tolerability in healthy volunteers (2025) ↗ · Carnosine and glucose metabolism: pilot trial (2016) ↗ · Carnosine and beta-alanine in human medicine: review (2023) ↗
Safety & what remains unknown
The trial’s size and duration provide limited information about uncommon effects and long-term use.
Source: Effects of carnosine supplementation on glucose metabolism: Pilot clinical trial. · 2016 ↗
Evidence boundaries
Small pilot and subgroup findings do not establish prevention of type 2 diabetes or treatment of neurological disease.
Source: Effects of carnosine supplementation on glucose metabolism: Pilot clinical trial. · 2016 ↗
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Category 3 (nominated without enough support)
Listed in 503A category 3 ("L-Carnosine", nominated without adequate support). source - World Anti-Doping Agency (2026)
- Not on the WADA Prohibited List
Not named. It is a common dietary-supplement ingredient; no prohibited class applies on the 2026 List. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & identity
This profile concerns carnosine itself. Beta-alanine supplementation is a different intervention, even though it can be discussed in relation to carnosine.
Source: Effects of carnosine supplementation on glucose metabolism: Pilot clinical trial. · 2016 ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.
Biology & proposed mechanism
The featured trial evaluated metabolic markers rather than establishing the relevance of every proposed antioxidant or antiglycation mechanism.
Source: Effects of carnosine supplementation on glucose metabolism: Pilot clinical trial. · 2016 ↗
Questions worth asking
- Does this pilot prove diabetes prevention?
- What material, population, and route were actually studied?
- Small pilot and subgroup findings do not establish prevention of type 2 diabetes or treatment of neurological disease.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Does this pilot prove diabetes prevention?
No. It measured short-term metabolic markers rather than new diabetes diagnoses over long follow-up.
Source: Effects of carnosine supplementation on glucose metabolism: Pilot clinical trial. · 2016 ↗
Does the publication verify a supplier’s product?
No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.
Source: Effects of carnosine supplementation on glucose metabolism: Pilot clinical trial. · 2016 ↗
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
